Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering)

CD19 CAR-T细胞疗法（中源协和细胞基因工程）

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLymphoma, B-Cell

Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A